论文部分内容阅读
阿司匹林作为心血管疾病的二线预防药的有益作用已被证实,其作为首选预防药的可能性必须与其潜在的危险性相权衡。此文对阿司匹林的胃肠毒性(脑出血后用阿司匹林的最严重的并发症)作了概述。此文包括1974～1989年抗血小板试验协作组中所有用阿司匹林预防心血管疾病的21组随机对照试验。受试者20011人,对照组19635人,80％为男性,且大多为中年人。用药剂量在50～1500mg/d不等。用药后平均随访时间为1～5.16年。结果提示,用阿司匹林后备类消化道症状发生率明显增加,出现金消化道出血,
The beneficial effects of aspirin as a second-line agent for cardiovascular disease have been demonstrated, and its potential as a preferred prophylactic drug must be weighed against its potential risk. This article summarizes the gastrointestinal toxicity of aspirin (the most serious complication of aspirin after cerebral hemorrhage). This article includes all randomized controlled trials of 21 randomized controlled trials of aspirin for the prevention of cardiovascular disease in the Antiplatelet Trial Collaboration from 1974 to 1989. 20011 subjects, 19635 control subjects, 80% men, and mostly middle-aged. Dosage at 50 ~ 1500mg / d range. After treatment, the average follow-up time was 1 ~ 5. 16 years. The results suggest that aspirin reserve type gastrointestinal symptoms significantly increased the incidence of gold gastrointestinal bleeding,